Lifestyle-Linked CV Risk: Where Does Aspirin Fit? Dr. Nishant Tripathy13 Feb 2026 12:45 PM ISTIndia faces a rapidly evolving cardiometabolic risk landscape, with overweight and obesity affecting 23.5% and 6.7% of adults, alongside escalating...
Redefining Diabetes Management With Dapagliflozin and Sitagliptin FDC: An Early, Effective and Sustainable Option For T2D Management With Risk Factors Dr. Vaishali Deskhmukh12 Feb 2026 12:40 PM ISTType 2 diabetes in Indians follows a distinct and more aggressive trajectory, marked by higher insulin resistance, early Beta-cell dysfunction, lower...
Considering Triple Agents in Glucose Control - Application & Safety Considerations in 2026 Dr. Bhumika Maikhuri11 Feb 2026 11:00 AM ISTIn this episode of The Diabetes Wellness Forum, titled "Considering Triple Agents-Application & Safety Considerations in 2026," Dr Nandita Mohan...
Case Management of Chemotherapy Induced Anemia (CIA) with Darbepoetin Alfa in a Patient with Metastatic Breast Carcinoma - Dr Adwaita Gore Swapnil Sharma9 Feb 2026 10:45 AM ISTIn this video, Dr. Adwaita A. Gore, Medical Oncologist at S L Raheja Hospital, Mumbai, presents a real-world case highlighting the management of...
ROBUST Study Released: One of the Largest Beta-Blocker KAP Study Captures Place of Beta Blockers in Indian Real-World Practice Prem Aggarwal7 Feb 2026 12:08 PM ISTOne of the largest Indian KAP studies including doctors in cardiovascular medicine practice has shown that metoprolol continues to be the most...
Obesity-Prediabetes Duo: Why Clinicians Must Intervene Early? Dr. Siddhant Milind Dahale4 Feb 2026 12:30 PM ISTPrediabetes is alarmingly common, with the IDF 2025 Atlas estimating nearly 90 million Indians are affected. [1] Escalating obesity,...
SURPASS-2- Tirzepatide vs Semaglutide in Type 2 Diabetes Deeksha Bhandari4 Feb 2026 12:30 PM ISTKey Summary: In addition to meeting the primary objective of noninferiority to semaglutide in type 2 diabetes (T2D), tirzepatide, at a dose of...
Efficacy and Safety of Dapagliflozin-Vildagliptin in Indian T2DM Patients with CV Risk Factors Dr. Bhumika Maikhuri30 Jan 2026 12:58 PM ISTThe Fixed-Dose Combination (FDC) of Dapagliflozin 5 mg + Vildagliptin 50 mg demonstrated significant improvements in Glycemic Control, Metabolic...
SURPASS-2: Superior HbA1c and Weight Reduction With Tirzepatide vs. Semaglutide Deeksha Bhandari29 Jan 2026 11:00 AM ISTThe SURPASS-2 trial compared three doses of tirzepatide (5 mg, 10 mg, 15 mg) with semaglutide 1 mg, in adults with type 2 diabetes who were already...
Regulatory Approval Granted for Reformulated Ranitidine Swapnil Sharma29 Jan 2026 10:00 AM ISTThe U.S. FDA has approved reformulated ranitidine tablets, marking the reintroduction of this widely used H2 receptor antagonist following extensive...
Robust Glycemic Control & Cardio-Renal Protection: Meeting the Advanced Needs of Indian Uncontrolled T2D with Empagliflozin, Sitagliptin, Metformin Dr. Nilanjan Sengupta28 Jan 2026 12:45 PM ISTIndia has an estimated 90 million people living with T2D [1] amid rising obesity and doubled management costs. Uncontrolled T2DM and early-onset...
Evaluation of Biologic Efficacy and Cost per NNT in Moderate-to-Severe Psoriasis: Indian Analysis Dr. Bhumika Maikhuri22 Jan 2026 10:30 AM ISTEvaluation of Biologic Efficacy and Cost per NNT in Moderate-to-Severe Psoriasis: Indian Analysis. Ixekizumab and ustekinumab were the most...
